End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.1 DKK | -8.82% | -9.45% | -48.73% |
16/04 | Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients | CI |
12/04 | Curasight A/S Announces Board Changes | CI |
Sales 2024 * | - | Sales 2025 * | 43M 6.17M 514M | Capitalization | 181M 25.96M 2.16B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 35M 5.02M 418M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 4.21 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 4 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.23% |
1 day | -8.82% | ||
1 week | -9.45% | ||
Current month | -16.51% | ||
1 month | -15.35% | ||
3 months | -52.85% | ||
6 months | -53.09% | ||
Current year | -48.73% |
Managers | Title | Age | Since |
---|---|---|---|
Carsten Nielsen
FOU | Founder | 41 | 01/13/01 |
Jacob Madsen
FOU | Founder | 52 | 01/13/01 |
Andreas Kjaer
FOU | Founder | 61 | 01/13/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kirsten Drejer
BRD | Director/Board Member | 68 | 04/21/04 |
Per Falholt
CHM | Chairman | 65 | 01/20/01 |
Chief Executive Officer | 57 | 01/16/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 9.1 | -8.82% | 5,234 |
25/24/25 | 9.98 | +0.20% | 890 |
24/24/24 | 9.96 | -1.39% | 6,953 |
23/24/23 | 10.1 | +0.50% | 4,633 |
22/24/22 | 10.05 | 0.00% | 13,286 |
End-of-day quote NORDIC GROWTH MARKET, April 26, 2024
More quotesChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-48.73% | 25.92M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CURAS Stock